D. Boral Starts Coverage on Turn Therapeutics with Buy Rating and $8 Target
D. Boral Capital begins coverage of Turn Therapeutics with a Buy rating, citing strong dermatology focus, upcoming clinical data, and long-term growth potential.
NOTRELOAD AI
Needham Raises Autolus Target to $11, Sees Strong Upside Into 2026
Needham boosts Autolus Therapeutics price target to $11, keeps Buy rating, and highlights breakeven potential and upside from obe-cel and Aucatzyl.
FDA Questions INOVIO's Fast-Track Approval for INO-3107
INOVIO's INO-3107 faces FDA scrutiny as agency questions accelerated approval eligibility for rare throat disease treatment.
Ultragenyx's Bone Disease Drug Fails Key Clinical Trials
Ultragenyx's setrusumab fails to reduce fractures in osteogenesis imperfecta patients in Phase 3 trials, though bone density improved. Company plans expense cuts.
Ulixacaltamide Receives FDA Breakthrough Designation for Tremor Treatment
Praxis Precision Medicines receives FDA Breakthrough Therapy Designation for ulixacaltamide, a promising new treatment for essential tremor affecting 7 million Americans.
BTIG Boosts Praxis Precision Price Target, Calls It a Top Pick for 2026
BTIG raises its price target on Praxis Precision to $843, citing strong prospects for its essential tremor drug Ulixacaltamide and major growth potential ahead of 2026.